Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2730689 | 0.89 | SMN1; SMN2 (0.85) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL1567228 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2KMT2AMEN1TP53HPGD | |
| SCHEMBL13049648 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL4424117 | 0.84 | KMT2A (0.68) | SMN1; SMN2KMT2AMEN1ALDH1A1NR1H4 | |
| SCHEMBL7314826 | 0.83 | KMT2A (0.71) | KMT2AMEN1ALDH1A1NR1H4EPHX2 | |
| SCHEMBL1565360 | 0.82 | SELL (0.66) | SMN1; SMN2KMT2AMEN1ALDH1A1SRD5A2 | |
| SCHEMBL1566154 | 0.81 | CA1 (0.65) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL11414793 | 0.81 | FFAR1 (0.67) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL16550429 | 0.81 | FFAR1 (0.67) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL3662909 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889876-B2 | Histone deacetylase inhibitors and uses thereof | JIANGSU HENGYI PHARMACEUTICAL CO., LTD. (CN) | 2014-11-18 | — | — | US | disclosed |
| US-20110152323-A1 | Histone deacetylase inhibitors and uses thereof | JIANGSU GOWORTH INVESTMENT CO. LTD (CN) | 2011-06-23 | — | — | US | disclosed |
| EP-2308868-A1 | HISTONE DEACETYLASE INHIBITORS AND USES THEREOF | Jiangsu Goworth Investment Co. Ltd (CN) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152323-A1 | Histone deacetylase inhibitors and uses thereof | HDAC1, HDAC11, HDAC5 | SMN1; SMN2 3776/4885KMT2A 45/4885NPC1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.